Increase to 900 mg BID
For a patient with a lithium level of 0.6 mEq/L on 1500 mg daily (600 mg AM, 900 mg PM), increase to 900 mg twice daily to achieve the target therapeutic range of 0.6-1.2 mEq/L for maintenance treatment. 1
Rationale for Dose Adjustment
Your patient's current level of 0.6 mEq/L sits at the absolute lower boundary of the therapeutic range. The FDA-approved lithium label specifies that maintenance therapy requires serum levels of 0.6-1.2 mEq/L, typically achieved with 300 mg three or four times daily 1. Your patient is receiving 1500 mg total daily, which is producing subtherapeutic levels.
The 900 mg BID regimen (1800 mg total daily) represents a 20% dose increase from the current 1500 mg, which should raise the serum level proportionally into the mid-therapeutic range (approximately 0.7-0.8 mEq/L). This is the most logical next step.
Why Not the Other Options?
600 mg AM + 1200 mg PM (1800 mg total): While this provides the same total daily dose, the uneven distribution creates unnecessarily high peak levels at night, increasing toxicity risk without therapeutic benefit 2, 3
Maintaining current dose: A level of 0.6 mEq/L provides minimal therapeutic coverage and risks treatment failure, particularly for mood stabilization where levels of 0.8-1.0 mEq/L are often more effective 4
Dosing Schedule Considerations
Twice-daily dosing is preferred over uneven split dosing for several reasons:
- More stable serum concentrations throughout the day, reducing peak-related side effects 3
- Better tolerability with sustained-release formulations when given BID 3
- Equivalent efficacy to three-times-daily dosing with improved compliance 5
While once-daily dosing at bedtime is increasingly used and may reduce polyuria 5, 6, switching from your patient's established BID pattern to once-daily would require different monitoring and is unnecessary at this stage.
Monitoring Protocol
After increasing to 900 mg BID:
- Check lithium level in 5-7 days (after steady state is reached) 1
- Draw level 12 hours post-dose (before morning dose if taking BID) 1
- Target range: 0.8-1.0 mEq/L for optimal maintenance therapy
- Monitor renal function (creatinine, eGFR) and electrolytes concurrently 7, 8
- Assess for early toxicity signs: tremor, confusion, ataxia, or GI symptoms 1
Critical Safety Considerations
Lithium toxicity occurs at doses close to therapeutic levels 1. Key precautions:
- Avoid NSAIDs, which reduce lithium clearance and increase toxicity risk 7
- Monitor for drug interactions with ACE inhibitors, ARBs, and diuretics 7
- Temporarily discontinue during acute illness, dehydration, or before procedures 8
- Elderly patients may require lower targets (0.6-0.8 mEq/L) due to reduced clearance 1, 9
Expected Timeline
With the increased dose of 900 mg BID, expect:
- Steady-state levels achieved in 5-7 days (approximately 5 half-lives)
- Clinical response assessment after 2-4 weeks at stable therapeutic levels
- Once stabilized, monitor levels every 2 months during maintenance 1
The 900 mg BID regimen provides a rational, evidence-based dose escalation that balances efficacy with safety while maintaining a convenient twice-daily schedule.